Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.

about

Regulatory T Cells in Systemic Sclerosis

P2860

Q58122062-3EE635A8-3030-4393-8773-128ED8730A37

P2860

Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.

Item

http://www.wikidata.org/entity/Q52316320

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Prophylactic and Therapeutic E ...... nic Graft-Versus-Host Disease.

@en

Prophylactic and Therapeutic Effects of Interleukin-2

@nl

type

Item

label

Prophylactic and Therapeutic E ...... nic Graft-Versus-Host Disease.

@en

Prophylactic and Therapeutic Effects of Interleukin-2

@nl

prefLabel

Prophylactic and Therapeutic E ...... nic Graft-Versus-Host Disease.

@en

Prophylactic and Therapeutic Effects of Interleukin-2

@nl

P1476

Prophylactic and Therapeutic E ...... nic Graft-Versus-Host Disease.

@en

P2093

Antonius Rolink

http://www.w3.org/2001/XMLSchema#string

Johanna Rolink

http://www.w3.org/2001/XMLSchema#string

Jonas Lötscher

http://www.w3.org/2001/XMLSchema#string

Matthias Kreuzaler

http://www.w3.org/2001/XMLSchema#string

Stefan Heiler

http://www.w3.org/2001/XMLSchema#string

P2860

Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus

Follicular Helper T Cells in Systemic Lupus Erythematosus: Why Should They Be Considered as Interesting Therapeutic Targets?

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Follicular helper CD4 T cells (TFH)

Central memory and effector memory T cell subsets: function, generation, and maintenance

IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25

Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.

The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.

P304

656

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2018.00656

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29670626

http://www.w3.org/2001/XMLSchema#string

P932

5893767

http://www.w3.org/2001/XMLSchema#string

Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.

about

P2860

P2860

Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932